The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.
07/12/2024
ESMO Colloquium supported by AbbVie:
Hot topics in ovarian cancer: Platinum resistance and emerging therapies
- Welcome and introduction
Ilaria Colombo - Insights from the biology of cancer of the ovaries, fallopian tube and peritoneum: The promise of biomarkers
Kosei Hasegawa - A clinical case of a patient with platinum-resistant ovarian cancer: Resistance pathways and state-of-the-art treatment options
Asima Mukhopadhyay - The promise of antibody drug conjugates (ADCs) in ovarian cancer: Mechanisms of action and emerging therapeutics
Clare L. Scott - A clinical case of a patient on anti-folate receptor ADC: Efficacy and safety data from registrational trials
Ilaria Colombo - Q&A, discussion and concluding remarks
Clare L. Scott
08/12/2024
ESMO Colloquium supported by Astellas:
Locally advanced and metastatic urothelial cancer (UC): State-of-the-art management in the new continuum of care
- Introduction and background of locally advanced and metastatic urothelial cancer
Ignacio Duran - Optimal definition of patient populations: Platinum eligibility and biology-informed science
Thomas B. Powles - ESMO Guidelines on state-of-the-art management of patients with first-line locally advanced and metastatic urothelial cancer and applicability in Asia Pacific
Xinan Sheng - Continuum of care after progression on first-line therapy: Testing and rationalising
Ignacio Duran - Optimal management of ADC toxicities in patients with urothelial malignancies
Andrew J. Weickhardt - Case presentation of a patient with metastatic urothelial cancer: Criteria for choosing the right regimens in first-line and second-line locally advanced and metastatic urothelial cancer
Eun Hee Jung - Panel discussion
- Summary and conclusion
Thomas B. Powles